These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15784627)

  • 1. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis.
    Bernatsky S; Hudson M; Suissa S
    Rheumatology (Oxford); 2005 May; 44(5):677-80. PubMed ID: 15784627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antirheumatic drug use and the risk of acute myocardial infarction.
    Suissa S; Bernatsky S; Hudson M
    Arthritis Rheum; 2006 Aug; 55(4):531-6. PubMed ID: 16874796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of hospitalized infection in patients with rheumatoid arthritis.
    Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
    J Rheumatol; 2008 Mar; 35(3):387-93. PubMed ID: 18260176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.
    Bernatsky S; Hudson M; Suissa S
    Rheumatology (Oxford); 2007 Jul; 46(7):1157-60. PubMed ID: 17478469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
    Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
    Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.
    Suissa S; Hudson M; Ernst P
    Arthritis Rheum; 2006 May; 54(5):1435-9. PubMed ID: 16645972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
    Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
    Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
    Hudson M; Rahme E; Richard H; Pilote L
    Arthritis Rheum; 2007 Apr; 57(3):516-23. PubMed ID: 17394181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antirheumatic drugs and the risk of tuberculosis.
    Brassard P; Kezouh A; Suissa S
    Clin Infect Dis; 2006 Sep; 43(6):717-22. PubMed ID: 16912945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung cancer after exposure to disease modifying anti-rheumatic drugs.
    Bernatsky S; Clarke A; Suissa S
    Lung Cancer; 2008 Feb; 59(2):266-9. PubMed ID: 17673329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.
    Nicola PJ; Maradit-Kremers H; Roger VL; Jacobsen SJ; Crowson CS; Ballman KV; Gabriel SE
    Arthritis Rheum; 2005 Feb; 52(2):412-20. PubMed ID: 15692992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.
    Brassard P; Lowe AM; Bernatsky S; Kezouh A; Suissa S
    Arthritis Rheum; 2009 Mar; 61(3):300-4. PubMed ID: 19248128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F; Michaud K; Stephenson B; Doyle J
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
    Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
    Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis.
    Nicola PJ; Crowson CS; Maradit-Kremers H; Ballman KV; Roger VL; Jacobsen SJ; Gabriel SE
    Arthritis Rheum; 2006 Jan; 54(1):60-7. PubMed ID: 16385496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis.
    Bernatsky S; Clarke AE; Suissa S
    Arch Intern Med; 2008 Feb; 168(4):378-81. PubMed ID: 18299492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.